Skip to main content
SpringerLink
Log in
Book cover

Renal Anemia pp 81–88Cite as

Do race, gender or mode of dialysis modulate erythropoietin response?

  • Chapter

  • 110 Accesses

Abstract

The introduction of erythropoietin (EPO) for the anemia of renal failure has clearly been one of the most important clinical advances in the treatment of end stage renal disease (ESRD). The benefits attributed to EPO use include improvement in cardiac function [1], quality of life [2], cognitive function [3] and increased sexual functioning [4] among others. To accrue these benefits, the hematocrit level is “targeted” to be between 33–36 vols % [5].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Pascual J, Teruel JL, Moya JL, Liano F, Jiminez-Mena M, Ortuno J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: A prospective study. Clin Nephrol. 1991;35:280–7.

    CAS  Google Scholar 

  2. Delano EG. Improvements in quality of life following treatment with r-HurEPO in anemic hemodialysis patients. Am J Kidney Dis. 1989;14:S14–18.

    Google Scholar 

  3. Wolcott DL, Marsh JT, La Rue A, Carr C, Nissenson AR. Recombinant human erythropoietin treatment may improve quality of life and cognitive function in chronic hemodialysis patients. Am J Kidney Dis. 1989;14:478–85.

    PubMed  CAS  Google Scholar 

  4. Schaefer RM, Kobot F, Heidland A. Impact of recombinant erythropoietin in sexual potency in hemodialysis patients: Contrib Nephrol. 1989;76:273–82.

    PubMed  CAS  Google Scholar 

  5. NKF/DOQI Guidelines. Am J Kidney Dis. 2001;37:S186–7.

    Google Scholar 

  6. Sehgal AR. Outcomes of renal replacement therapy among blacks and women. Am J Kidney Dis. 2000;35:S148–52.

    Article  PubMed  CAS  Google Scholar 

  7. US Renal Data System. USRDS 2000 Annual Data Report. Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2000.

    Google Scholar 

  8. Greer JW, Milam RA, Eggers PW. Trends in use, cost and outcomes of human recombinant erythropoietin, 1989–1998. Health Care Finance Rev. 1999;20:55–62.

    CAS  Google Scholar 

  9. Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis. 2000;36:282–93.

    Article  PubMed  CAS  Google Scholar 

  10. Daumit GL, Herman JA, Powe NR. Relation of gender and health insurance to cardiovascular procedure use in persons with progression of chronic renal disease. Med Care. 2000;38:354–65.

    Article  PubMed  CAS  Google Scholar 

  11. Madore F, Lowrie EG, Brugnara C, et al. Anemia in hemodialysis patients: variables affecting this outcome predictor. J Am Soc Nephrol. 1997; 8:1921–9.

    PubMed  CAS  Google Scholar 

  12. Ifudu O, Uribarri J, Rajwant I, et al. Gender modulates responsiveness to recombinant erythropoietin. Am J Kidney Dis. 2001;38:518–22.

    Article  PubMed  CAS  Google Scholar 

  13. Goodnough LT, Price TH, Parvin CA. The endogenous erythropoietin response and the erythropoietic response to blood loss anemia: the effects of age and gender. J Lab Med. 1995;126:57–64.

    CAS  Google Scholar 

  14. Rocco MV, Frankenfield DL, Frederick PR, Pugh J, McClellan WM, Owen WF. Intermediate outcomes by race and ethnicity in peritoneal dialysis patients: results from the 1997 ESRD Core Indicator Project. National ESRD Core Indicators Workgroups. Perit Dial Int. 2000;20:328–35.

    PubMed  CAS  Google Scholar 

  15. 2000 Annual Report ESRD Clinical Performance Measures Project. Am J Kidney Dis. 2001;37:S28.

    Google Scholar 

  16. Ifudu O, Dawood M, Iofel Y, Valcourt JS, Friedman EA. Delayed referral of black, hispanic and older patients with chronic renal failure. Am J Kidney Dis. 1999;33: 728–33.

    Article  PubMed  CAS  Google Scholar 

  17. Thamer M, Richard CM, Klingmann J, Ivanovich P, Lang G, Cotter DJ. Use of clinical guideline for treatment of anemia among hemodialysis patients. Artif Organs. 2000;24:91–4.

    Article  PubMed  CAS  Google Scholar 

  18. Perry GS, Byers T, Yip R, Margen, S. Iron nutrition does not account for the hemoglobin difference between Blacks and Whites. J Nutrition. 1992; 122:1417–24.

    CAS  Google Scholar 

  19. Vasques EM, Beneditti A. Ethnic differences in clinical response to corticosteroid treatment of acute renal allograft rejection. Transplantation. 2001; 71:229–33.

    Article  Google Scholar 

  20. Matthew HW. Racial, ethnic and gender differences in response to medicines. Drug Metabol Drug Interact. 1995;12:77–91.

    Google Scholar 

  21. Cushman WC, Reda, DJ, Perry HM, Williams D, Abjellatif M, Materson BJ. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. VA Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 2000;27:825–31.

    Article  Google Scholar 

  22. Frackiewicz EJ, Samek JJ, Herrera JM, Kurtz NM, Cutler NR. Ethnicity and antipsychotic response. Ann Pharmacother. 1997;31:1360–9.

    PubMed  CAS  Google Scholar 

  23. Bargman JM, Oreopoulos DG. Complications other than peritonitis or those related to the catheter and the fate of uremic organ dysfunction in patients receiving peritoneal dialysis. In: KD Nolph (ed.), Peritoneal Dialysis, Kluwer Academic Publisher, Boston, p 299. 1989.

    Google Scholar 

  24. Mehta BR, Mogridge C, Bell JD. Changes in red cell mass, plasma volume and hematocrit in patients on CAPD. Trans Amer Soc Artif Intern Organs. 1983;29; 50–2.

    CAS  Google Scholar 

  25. Zappacosta AR, Carlo J, Erslev A. Normalization of hematocrit in patients with ESRD on CAPD. Am J Med. 1982;72:53–62.

    Article  PubMed  CAS  Google Scholar 

  26. De Paepe M, Schelstraete K, Ringoir S. Influences of continuous ambulatory peritoneal dialysis on the anemia of endstage renal disease. Kidney Int. 1983;23: 744–8.

    Article  PubMed  Google Scholar 

  27. Movilli E, Natale C, Cancarini G. Improvements of iron utilization and anemia in uremic patients switched from hemodialysis to continuous peritoneal dialysis. Perit Dial Bull. 1986;6:147–9.

    Google Scholar 

  28. Page DE, House A. Important cost differences of blood transfusions and erythropoietin between hemodialysis and peritoneal dialysis patients. Adv Perit Dial. 1998;14:87–9.

    PubMed  CAS  Google Scholar 

  29. Sezer S, Ozdemir N, Arat Z, et al. What happens after conversion of treatment to continuous ambulatory peritoneal dialysis from hemodialysis? Adv Perit Dial. 2000;16:177–81.

    PubMed  CAS  Google Scholar 

  30. Lopez-Menchero R, Miguel A, Garcia-Ramon R, Perez-Contreras J, Girbes V. Importance of residual renal function in CAPD: its influence on different parameters of renal replacement therapy. Nephron. 1999;83:219–25.

    Article  PubMed  CAS  Google Scholar 

  31. Opatrny K, Opatrna S, Sefrna F, Wirth J. The anemia in continuous ambulatory peritoneal dialysis patients is related to Kt/V index. Artif Organs. 1999;23:65–9.

    Article  PubMed  Google Scholar 

  32. Ifudu O, Feldman J, Friedman EA. The intensity of hemodialysis and the response to erythropoietin in patients with end-stage renal disease. N Engl J Med. 1996; 334:420–5.

    Article  PubMed  CAS  Google Scholar 

  33. Lacson E, Diaz-Buxo JA. Daily and nocturnal hemodialysis: How do they stack up? Amj Kidney Dis. 2001;38:225–39.

    Article  CAS  Google Scholar 

  34. Bonomini V, Miolo V, Albertazzi A, Scolari P. Daily dialysis programme: Indications and results. Proc Eur Dial Transplant Assn. 1972;9:44–52.

    CAS  Google Scholar 

  35. Bouncristiani U, Ouintaliani G, Cozzari M, Giombini LRM. Daily dialysis: long term clinical and metabolic results. Kidney Int. 1988;33:S137–40.

    Google Scholar 

  36. Ting G. The effects of daily dialysis on the hematocrit and blood pressure. NIH/ NIDDKD Task Force on Daily Dialysis, Bethesda, MD, 2001:16–17.

    Google Scholar 

Download references

Authors
  1. Barbara G. Delano
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Inpatient Dialysis Services, SUNY Downstate Medical Center, Brooklyn, New York, USA

    Onyekachi Ifudu (Associate Professor of Medicine, Director) (Associate Professor of Medicine, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Delano, B.G. (2002). Do race, gender or mode of dialysis modulate erythropoietin response?. In: Ifudu, O. (eds) Renal Anemia. Springer, Dordrecht. https://doi.org/10.1007/978-94-015-9998-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-94-015-9998-6_8

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-90-481-6045-7

  • Online ISBN: 978-94-015-9998-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation